RxDoctor Payments Data

Cristina Dasoveanu, MD

Internal Medicine · Alpharetta, GANPI 1649229428

Payments from drug & device makers

$1,612in general payments, 2019–2025

Across 91 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$351
  • AstraZeneca$197
  • Lilly USA, LLC$176
  • Exact Sciences$126
  • Novo Nordisk$124
  • Sanofi-aventis U.S. LLC$93
  • plus $546 from 15 others

What the payments were for

  • Food & beverage$1,612100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,612 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$72,514
Medicare patients
282
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$43,391
JardianceEmpagliflozin31$41,698
TrulicityDulaglutide31$33,065
FarxigaDapagliflozin Propanediol26$29,905
JanuviaSitagliptin Phosphate17$28,223
EliquisApixaban22$26,919
MounjaroTirzepatide17$17,752
Breo ElliptaFluticasone/Vilanterol21$10,767
SymbicortBudesonide/Formoterol Fumarate12$5,212
SynthroidLevothyroxine Sodium41$4,931
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,538
Rosuvastatin Calcium224$3,174
Levothyroxine Sodium348$2,571
Atorvastatin Calcium451$2,407
Losartan Potassium246$1,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$176$50,81748 claims
Novo NordiskOzempic$124$43,39146 claims
Boehringer IngelheimJardiance$16$41,69831 claims
AstraZenecaFarxiga, Symbicort$197$35,11738 claims
MerckJanuvia$39$28,22317 claims
PfizerEliquis$73$26,91922 claims
GSKBreo Ellipta$39$10,76721 claims
AbbVieSynthroid$351$4,93141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →